PD-1 inhibitors

All PD-1 inhibitors Articles

• SCRT plus ICI associated with higher CR and pCR rates than LCRT in rectal cancer
• PD-1/PD-L1 inhibitor plus chemotherapy improves overall survival in advanced gastric and esophageal junction cancer
• PD-1/PD-L1 inhibitors provide superior overall survival compared to chemotherapy or cetuximab in platinum-refractory HNSCC
• PD-1 and PD-L1 inhibitors increase the risk of skin rash in cancer patients
• Multi-parameter models of inhibitory receptor states could better predict immunotherapy response and toxicity
• Viral mimicry induction via epigenetic therapies and DNA damage may convert cold tumors to hot
• Combination of PD-1/PD-L1 inhibitors and chemotherapy shows no overall survival benefit in mCRPC
• Combination Immunotherapy Improves Outcomes for BCG Unresponsive Non Muscle Invasive Bladder Cancer
• High tumor mutational burden correlates with improved objective response rate in HNSCC patients
• Forty-seven clinically relevant late-phase programs identify development trajectories for PD-1 and PD-L1 therapies through 2030
• PD-1 inhibitor plus chemotherapy improves progression-free survival and overall survival in driver gene-negative NSCLC
• Primary and acquired resistance to immune checkpoint inhibitors in NSCLC involves antigen presentation and TME remodeling
• Comparative Efficacy of PD-1 and PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
• Multidimensional models incorporating genomic and microenvironment features likely outperform single-analyte tests to predict immunotherapy response
• PD-1 inhibitors plus chemotherapy achieve 64% objective response rate in recurrent or metastatic nasopharyngeal carcinoma
• Hodgkin lymphoma survival exceeds 90% in early-stage patients with modern therapy
• PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer
• Systematic review of immune checkpoint inhibitors in cancer efficacy and safety
• Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
• Disitamab vedotin plus PD-1 inhibitor showed high response rates in urothelial carcinoma patients across six centers
• HBV-positive status linked to higher surgical conversion in unresectable HCC receiving triple therapy
• Review of immunotherapy innovations for triple-negative breast cancer survival
• Narrative review discusses immune checkpoint inhibitors in lung cancer patients
• Systematic review examines immunotherapy resistance mechanisms and strategies in hepatocellular carcinoma patients
• Systematic review examines immune checkpoint inhibitors, innate immunity, and immune-related adverse events in cancer patients
• PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
• Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors